NASDAQ · Healthcare
Gilead Sciences, Inc. (GILD) stock research
Gilead Sciences, Inc. (GILD) is listed on NASDAQ. Gilead Sciences, Inc. reported revenue of $29.4B in the fiscal year that ended on 2025-12-31. Revenue rose 2.4% from the year before. Gilead Sciences, Inc.’s net income for that year was $8.5B. The SEC classifies it under Biological Products, (No Diagnostic Substances). It is incorporated in Delaware. Its most recent SEC filing is Form 10-Q (quarterly report), filed on 2026-08-06.
Open GILD in Willow. Filings, fundamentals, recent news — sourced stock research, no recommendation.
Annual financials
As tagged by Gilead Sciences, Inc. in its annual reports on SEC EDGAR. The latest year is from Form 10-K, filed on 2026-02-24.
| Fiscal year ended | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2025-12-31 | $29.4B | $8.5B | $6.78 |
| 2024-12-31 | $28.8B | $480.0M | $0.38 |
| 2023-12-31 | $27.1B | $5.7B | $4.50 |
Recent SEC filings
Filed with the SEC under CIK 0000882095. Every row is read from the filing itself on EDGAR, not from a summary of it.
- 10-Q (quarterly report) filed 2026-08-06 · period ending 2026-06-30
- 8-K (current report) filed 2026-08-04 · period ending 2026-08-04
- 8-K (current report) filed 2026-05-20 · period ending 2026-05-14
- 10-Q (quarterly report) filed 2026-05-07 · period ending 2026-03-31
- 8-K (current report) filed 2026-05-07 · period ending 2026-05-07
- 8-K (current report) filed 2026-05-04 · period ending 2026-04-30
Filing history read from SEC EDGAR on 2026-10-19.
What a Willow brief on GILD checks
- Recent filings and company disclosures.
- TTM fundamentals and valuation context.
- Recent news and market context separated from primary filings.
- Bull case, bear case, key risks, and watch-next items in a non-directional register.
Questions about GILD
- What was Gilead Sciences, Inc.’s revenue in the fiscal year ended 2025-12-31?
- $29.4B for the fiscal year that ended on 2025-12-31, as reported in Form 10-K filed on 2026-02-24.
- Was Gilead Sciences, Inc. profitable in the fiscal year ended 2025-12-31?
- Yes. It reported net income of $8.5B for the fiscal year that ended on 2025-12-31.
- What were Gilead Sciences, Inc.’s diluted earnings per share in the fiscal year ended 2025-12-31?
- $6.78 per diluted share for the fiscal year that ended on 2025-12-31.
- What is Gilead Sciences, Inc.’s most recent SEC filing?
- Form 10-Q (quarterly report), filed on 2026-08-06. brief.finance reads it directly from SEC EDGAR.
- When does Gilead Sciences, Inc.’s fiscal year end?
- Its SEC registration lists the year end as 31 December. The annual figures on this page cover the fiscal year that ended on 2025-12-31.
- What is Gilead Sciences, Inc.’s SEC CIK number?
- 0000882095. EDGAR uses this Central Index Key to identify every filing the company submits.
- What does a Willow brief on GILD include?
- Recent SEC filings, fundamentals and valuation context, price history, and both a bull case and a bear case. Every figure links to the source it came from.
- Does brief.finance say whether to buy or sell GILD?
- No. brief.finance publishes educational research and does not recommend buying, selling, or holding any security.
Primary source paths
- SEC EDGAR company filings search
- Nasdaq market activity page
- brief.finance methodology and source checks
More Healthcare research hubs
- ABBV — AbbVie Inc.
- ABT — Abbott Laboratories
- AMGN — Amgen Inc.
- BIIB — Biogen Inc.
- BMY — Bristol-Myers Squibb Company
- CI — The Cigna Group
- CVS — CVS Health Corporation
- DHR — Danaher Corporation
- Browse all Healthcare research hubs
Author and editorial responsibility
By Joseph, Founder and editor, brief.finance. Every brief is generated under a fixed editorial and compliance method operated by Reaktif LLC.
About the author · Disclosures · Stock Directory
Ticker catalog last updated 2026-10-19.